Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

Hien K. Duong(Cleveland Clinic), Bipin N. Savani(Vanderbilt University Medical Center), Ed Copelan(Carolinas Healthcare System), Steven M. Devine(The Ohio State University), Luciano J. Costa(Medical University of South Carolina), John R. Wingard(University of Florida Health), Paul Shaughnessy(CHRISTUS Transplant Institute), Navneet S. Majhail(Cleveland Clinic), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Corey Cutler(Dana-Farber Cancer Institute), William Bensinger(Fred Hutch Cancer Center), Mark R. Litzow(Mayo Clinic), Mohamad Mohty(Sorbonne Université), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Helen Leather(University of Florida Health), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Paul A. Carpenter(Fred Hutch Cancer Center)
Biology of Blood and Marrow Transplantation
May 9, 2014
Cited by 210Open Access
Full Text

Abstract

Peripheral blood progenitor cell mobilization practices vary significantly among institutions. Effective mobilization regimens include growth factor alone, chemotherapy and growth factor combined, and, more recently, incorporation of plerixafor with either approach. Many institutions have developed algorithms to improve stem cell mobilization success rates and cost-effectiveness. However, an optimal stem cell mobilization regimen has not been defined. Practical guidelines are needed to address important clinical questions, including which growth factor is optimal, what chemotherapy and dose is most effective, and when to initiate leukapheresis. We present recommendations, based on a comprehensive review of the literature, from the American Society of Blood and Marrow Transplantation.


Related Papers

No related papers found

Powered by citation graph analysis